Article
Economics
Stefan M. Scholz, Felix Weidemann, Oliver Damm, Bernhard Ultsch, Wolfgang Greiner, Ole Wichmann
Summary: The study finds that vaccinating 2 to 9-year-olds with quadrivalent influenza vaccines is cost-saving in Germany, and extending the target group to 2 to 17-year-olds can increase health benefits. Even without vaccine-induced herd protection, childhood vaccination against seasonal influenza remains cost-effective.
Article
Immunology
Ramil R. Mintaev, Dina Glazkova, Olga Orlova, Elena Bogoslovskaya, German A. Shipulin
Summary: Scientists have developed an epitope-based universal vaccine rMVA-k1-k2 that provides effective protection against various strains of influenza virus. Double immunization with this vaccine has shown a 67% or greater efficiency in protecting mice against multiple subtypes of influenza A. The level of protection is comparable to other successful universal vaccines in clinical trials.
Article
Economics
Florian Zeevat, Pascal Crepey, F. Christiaan K. Dolk, Arjan J. Postma, Vidya N. A. Breeveld-Dwarkasing, Maarten J. Postma
Summary: Using quadrivalent influenza vaccine (QIV) instead of trivalent influenza vaccine (TIV) during the influenza seasons 2010 to 2018 in the Netherlands would have been cost-effective, potentially preventing an average of 9500 symptomatic influenza cases, 2130 outpatient visits, 84 hospitalizations, and 38 deaths per year. Retrospectively, this decision could have led to additional 385 QALYs and 398 life-years gained annually, with significant cost savings.
Article
Immunology
Kailey Hughes, Donald B. Middleton, Mary Patricia Nowalk, Goundappa K. Balasubramani, Emily T. Martin, Manjusha Gaglani, H. Keipp Talbot, Manish M. Patel, Jill M. Ferdinands, Richard K. Zimmerman, Fernanda P. Silveira
Summary: This study evaluated the vaccine effectiveness against influenza hospitalization among immunocompromised adults during the 2017-2018 influenza season. The results showed that while immunocompromised adults had a higher vaccination rate, their protection against influenza was lower, with a vaccine effectiveness of 33% in the overall adult population. Further research is needed to assess vaccine effectiveness among different immunocompromising conditions and explore ways to improve effectiveness for immunocompromised individuals.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Virology
Jiali Li, Yifan Zhang, Xinglong Zhang, Longding Liu
Summary: China has a high number of influenza cases and deaths, and the effectiveness of the flu vaccine is reduced due to viral antigenic drift. Therefore, the development of a universal influenza vaccine is necessary.
Article
Immunology
Dawei Zhu, Min Lv, Yunhua Bai, Jiang Wu, Ping He
Summary: This study analyzed the cost-effectiveness of introducing quadrivalent influenza vaccines (QIV) to school children, elderly adults, and healthcare workers (HCWs) in Beijing and found that it is the most cost-effective strategy.
Review
Immunology
Christopher L. D. McMillan, Paul R. Young, Daniel Watterson, Keith J. Chappell
Summary: Current influenza virus vaccines mainly induce antibodies against the highly variable head domain of the hemagglutinin protein, but these antibodies are often strain-specific, resulting in limited cross-protection. Therefore, the annual update of vaccine formulations to counteract the challenge of influenza virus evolution is crucial.
Review
Immunology
Kenneth Sik-Kwan Chan, Charlene Hoi-Lam Wong, Horace Cheuk-Wai Choi
Summary: This study assessed the cost-effectiveness of pediatric influenza vaccination with the intranasal live-attenuated influenza vaccine (LAIV). It found that the implementation of LAIV vaccination in the pediatric population is cost-effective when compared to other strategies. Factors such as the efficacy of LAIV for children, vaccination coverage, vaccine prices, and herd immunity were significant contributors to the cost-effectiveness.
Article
Biotechnology & Applied Microbiology
Pablo Manuel Bianculli, Lucile Bellier, Ignacio Olivera Mangado, Carlos Grau Perez, Gustavo Mieres, Luis Lazarov, Audrey Petitjean, Hugo Dibarboure, Juan Guillermo Lopez
Summary: This study evaluated the cost-utility of replacing trivalent influenza vaccine with quadrivalent influenza vaccine in Uruguay. The results showed that using quadrivalent influenza vaccine could avoid a considerable number of influenza cases and healthcare consultations, and save workdays. It is cost-effective, especially for the target populations in Uruguay, particularly for older adults.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Analia Uruena, Paula Micone, Cecilia Magneres, Joaquin Mould-Quevedo, Norberto Giglio
Summary: The study assessed the cost-effectiveness of using quadrivalent influenza vaccine compared to trivalent influenza vaccine in Argentina. The results showed that introducing the quadrivalent vaccine would prevent more influenza cases and be more cost-effective, particularly for individuals aged 65 and older.
Article
Immunology
Nathaniel M. Lewis, Jessie R. Chung, Timothy M. Uyeki, Lisa Grohskopf, Jill M. Ferdinands, Manish M. Patel
Summary: This study analyzes the comparability of relative vaccine effectiveness across different studies and suggests that this comparability is dependent on the absolute vaccine effectiveness of the comparator vaccine. These findings have implications for the design of influenza vaccine studies and data reporting.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Economics
Desmond Loong, Ba' Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Mueller, Sharon E. Straus, Andrea C. Tricco, Wanrudee Isaranuwatchai
Summary: Older adults are at high risk of influenza-related complications or hospitalization. This systematic review evaluates the cost-effectiveness of different influenza vaccine options for older adults. The findings suggest that quadrivalent inactivated vaccine (QIV), high-dose trivalent inactivated vaccine (TIV-HD), and adjuvanted trivalent inactivated vaccine (TIV-ADJ) are cost-effective compared to trivalent inactivated vaccine (TIV), with a willingness to pay threshold of $50,000 per quality-adjusted life-year. Future studies should employ robust methodologies, such as real-world evaluations or modeling studies, to account for methodological, structural, and parameter uncertainty.
Review
Virology
Wen-Chien Wang, Ekramy E. Sayedahmed, Suryaprakash Sambhara, Suresh K. Mittal
Summary: Influenza viruses are a major cause of millions of cases globally and pose a significant threat to public health. Current seasonal influenza vaccines provide limited protection and are less effective against mismatched strains. The development of a universal influenza vaccine targeting conserved antigen domains is underway to provide broader protection.
Article
Immunology
Van Hung Nguyen, Mansoor Ashraf, Joaquin F. F. Mould-Quevedo
Summary: This study evaluated the cost-effectiveness of an adjuvanted quadrivalent influenza vaccine for adults = 65 years in Ireland. The results showed that the vaccine is highly cost-effective from both payer and societal perspectives, with cost-effectiveness ratios below the threshold of EUR 45,000/QALY.
Article
Biotechnology & Applied Microbiology
Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond, Milton C. Weinstein
Summary: In the UK, the potential cost-effectiveness of vaccinating adults aged 65 years and above with MF59-adjuvanted quadrivalent influenza vaccine (aQIV) compared with high-dose quadrivalent influenza vaccine (QIV-HD) is similar, with QIV-HD needing to be priced similarly to aQIV in order to achieve cost-effectiveness.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Public, Environmental & Occupational Health
Eunha Shim, Shawn T. Brown, Jay DePasse, Mary Patricia Nowalk, Jonathan M. Raviotta, Kenneth J. Smith, Richard K. Zimmerman
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2016)
Article
Public, Environmental & Occupational Health
Kenneth J. Smith, Jonathan M. Raviotta, Jay V. DePasse, Shawn T. Brown, Eunha Shim, Mary Patricia Nowalk, Richard K. Zimmerman
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2016)
Article
Immunology
Manjusha Gaglani, Jessica Pruszynski, Kempapura Murthy, Lydia Clipper, Anne Robertson, Michael Reis, Jessie R. Chung, Pedro A. Piedra, Vasanthi Avadhanula, Mary Patricia Nowalk, Richard K. Zimmerman, Michael L. Jackson, Lisa A. Jackson, Joshua G. Petrie, Suzanne E. Ohmit, Arnold S. Monto, Huong Q. McLean, Edward A. Belongia, Alicia M. Fry, Brendan Flannery
JOURNAL OF INFECTIOUS DISEASES
(2016)
Article
Health Policy & Services
Chyongchiou Jeng Lin, Mary Patricia Nowalk, Richard K. Zimmerman, Krissy K. Moehling, Tracey Conti, Norma J. Allred, Evelyn C. Reis
JOURNAL OF PEDIATRIC HEALTH CARE
(2016)
Article
Immunology
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Article
Public, Environmental & Occupational Health
Kenneth J. Smith, Glenson France, Mary Patricia Nowalk, Jonathan M. Raviotta, Jay Depasse, Angela Wateska, Eunha Shim, Richard K. Zimmerman
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2019)
Article
Public, Environmental & Occupational Health
Sarah H. Yi, Kiran M. Perkins, Sophia V. Kazakova, Kelly M. Hatfield, David G. Kleinbaum, James Baggs, Rachel B. Slayton, John A. Jernigan
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2019)
Article
Immunology
Richard K. Zimmerman, Jeannette E. South-Paul, Gregory A. Poland
JOURNAL OF INFECTIOUS DISEASES
(2020)
Editorial Material
Immunology
Richard K. Zimmerman
Summary: Many people with religious convictions are hesitant about COVID-19 vaccines due to concerns about fetal cell lines, but religious texts and leaders support prevention and vaccination. Clinicians can address patient concerns through ethical analysis, altruism, religious support, and providing vaccines developed without fetal cell lines.
Article
Immunology
Angela R. Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: The study indicates that further research on parameters of pneumococcal vaccine uptake programs is not supported at commonly cited US cost-effectiveness benchmarks in adults. It is justifiable to conduct further research to reduce uncertainty in other aspects of adult pneumococcal vaccination.
Article
Immunology
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman
Summary: The COVID-19 pandemic has led to declines in childhood PCV13 vaccination rates, which could result in increased pneumococcal disease rates in seniors, impacting the economic favorability of PCV13 vaccination in older adults. Absolute decreases of over 50% in pediatric PCV13 vaccination over a two-year period would be needed to make intensified PCV13 use economically favorable in non-immunocompromised seniors.
Article
Public, Environmental & Occupational Health
Mary G. Krauland, David D. Galloway, Jonathan M. Raviotta, Richard K. Zimmerman, Mark S. Roberts
Summary: According to an agent-based model, the decrease in residual immunity caused by protective measures in the first season may lead to an increase in influenza cases in the subsequent season. The extent of the increase depends on cross-immunity from past infections and the transmissibility of influenza strains. Enhanced vaccine coverage or continued interventions to reduce transmission could help mitigate this high season, and young children may be at a higher risk due to limited exposure to infection in the previous year.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2022)
Article
Immunology
Bo Zhai, Karen Clarke, David L. Bauer, Krissy K. Moehling Geffel, Saran Kupul, Lucas J. Schratz, M. Patricia Nowalk, Anita K. McElroy, James B. McLachlan, Richard K. Zimmerman, John F. Alcorn
Summary: COVID-19 has had an unprecedented global impact on human health. Understanding the antibody memory responses to infection is crucial for controlling the pandemic. A study on convalescent patients with virologically confirmed SARS-CoV-2 infection found that serum antibody concentrations were variable and positively correlated with microneutralization activity and age. However, there was no correlation with participant sex, timing of blood sampling, or the number of SARS-CoV-2-specific B cells. Body mass index was also positively correlated with serum antibody levels. Age and body mass index were independently associated with antibody levels. These findings have implications for public health policy and vaccination programs.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Immunology
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: The introduction summarizes the CDC's recommendations for pneumococcal vaccination in older adults and the potential benefits of an in-development 21-valent vaccine (PCV21) compared to current recommendations. A decision model was used to compare the cost-effectiveness of PCV21 to current vaccines in Black and non-Black cohorts. The results indicate that PCV21 is likely to be economically and clinically favorable in older adults.
Article
Economics
Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Summary: This study estimated the societal cost of racial disparities in pneumococcal disease among US adults aged >= 50 years. The findings suggest that the racial disparities in costs are substantial and implementing policies and interventions could reduce these costs and improve health.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2023)